Alamar Biosciences Expands to Europe to Advance Precision Proteomics
Alamar Biosciences has made a significant move in furthering global scientific research by opening its European headquarters and distribution center in Milan, Italy. This expansion will support the commercialization of the company’s ARGO™ HT System and NULISA™ Platform, which are high-sensitivity biomarker solutions driving the earliest detection of disease.
The ARGO™ HT System is a fully automated, high-throughput precision proteomics platform that simplifies the process with just the push of a button. On the other hand, the NULISA™ Platform sets a new standard in proteomic analysis with attomolar sensitivity, enabling unprecedented biomarker detection and quantitation.
With the European headquarters established as the central hub for operations, Alamar Biosciences aims to enhance its ability to provide innovative products and outstanding customer service to its expanding base of European clients. The distribution center in Milan will ensure efficient and timely delivery of Alamar’s complete range of proteomics products, demonstrating the company’s commitment to meeting the evolving needs of the global research community.
Yuling Luo, Ph.D., Chairman, Founder, and CEO of Alamar Biosciences, expressed excitement about this strategic expansion and emphasized the company’s ongoing commitment to supporting the scientific community across Europe. The location of Milan was chosen for its dynamic environment and strategic positioning, enabling Alamar to better serve its customers and accelerate the delivery of cutting-edge solutions.
Key highlights of the expansion include enhanced customer service, improved distribution efficiency, commitment to growth, and leveraging Milan’s strategic location. Luigi Pirovano, Managing Director of Alamar Biosciences Europe, srl, highlighted the importance of supporting European research clients efficiently and emphasized the company’s logistical expertise and extensive experience in the life sciences sector.
Alamar Biosciences, Inc., a privately held life sciences company, stands by its mission to power precision proteomics for the early detection of diseases. By combining the NULISA Platform and ARGO™ HT System with the latest genomics advancements, the company achieves single-digit attomolar detection sensitivity, surpassing existing protein detection technology.
For more information about Alamar Biosciences and its precision proteomics solutions, visit alamarbio.com. Stay informed about the company’s latest updates and innovations by following Alamar Biosciences on YouTube.
Source link
